10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $622489 | -$47M | 64.3% | -8058.8% | -227.8% | -190.0% | -$30M | — | $12M |
| 2024 | $4M | -$38M | 74.5% | -1023.7% | -70.5% | -59.8% | -$30M | — | $3M |
| 2023 | $7M | -$35M | 38.6% | -626.9% | -41.3% | -37.1% | -$23M | — | $15M |
| 2022 | $34M | -$14M | 84.0% | -78.8% | -12.4% | -11.6% | $5M | — | $23M |
| 2021 | $98M | $37M | 88.2% | 47.1% | 27.3% | 22.9% | $40M | — | $89M |
| 2020 | $75M | $42M | 77.7% | 55.9% | 63.7% | 59.6% | $27M | — | $43M |
| 2019 | $214974 | -$6M | 47.7% | -2741.6% | -356.6% | -279.7% | -$6M | — | $893138 |
| 2018 | $39911 | -$6M | 76.5% | -15328.6% | 592.3% | -403.8% | -$4M | $4M | $950237 |
| 2017 | $7662 | -$7M | 96.1% | -59567.6% | -180.7% | -149.3% | -$3M | — | $4M |
| 2016 | — | -$2M | — | — | 64.4% | -148.8% | -$1M | — | $998737 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $166131 | -$6M | 72.7% | -3732.5% | -49.4% | -37.9% | -$7M | — | $4M |
| Mar '26 | $145954 | -$9M | -32.8% | -6309.1% | -57.0% | -42.5% | -$8M | — | $8M |
| Dec '25 | $263922 | -$26M | 46.0% | -10056.7% | -124.8% | -104.1% | -$6M | — | $12M |
| Sep '25 | $145380 | -$6M | 81.9% | -4824.5% | -14.8% | -13.2% | -$6M | — | $11M |
| Jun '25 | $162910 | -$8M | 80.3% | -4946.1% | -19.0% | -16.6% | -$9M | — | $11M |
| Mar '25 | $50277 | -$8M | 57.1% | -17009.7% | -15.9% | -13.7% | -$9M | — | $2M |
| Dec '24 | $149325 | -$11M | -70.8% | -7973.9% | -20.5% | -17.4% | -$8M | — | $3M |
| Sep '24 | $641141 | -$10M | 53.6% | -1596.4% | -15.2% | -13.4% | -$7M | — | $11M |
| Jun '24 | $3M | -$8M | 92.0% | -289.1% | -10.5% | -9.4% | -$5M | — | $14M |
| Mar '24 | $467854 | -$9M | 49.9% | -2192.9% | -11.9% | -10.7% | -$9M | — | $23M |
| Dec '23 | $4M | -$15M | 16.5% | -332.6% | -17.2% | -15.4% | -$5M | — | $15M |
| Sep '23 | $2M | -$6M | 89.6% | -363.7% | -6.0% | -5.5% | -$6M | — | $10M |
| Jun '23 | $197806 | -$9M | -132.1% | -6063.7% | -8.6% | -7.9% | -$6M | — | $14M |
| Mar '23 | $601957 | -$6M | 16.6% | -1653.0% | -5.2% | -4.9% | -$6M | — | $6M |
| Dec '22 | $1M | -$22M | 63.2% | -1863.8% | -19.1% | -17.8% | -$4M | — | $23M |
| Sep '22 | $5M | -$1M | 84.9% | -128.3% | -1.0% | -0.9% | $888274 | — | $82M |
| Jun '22 | $5M | -$3M | 81.8% | -82.6% | -1.9% | -1.7% | $1M | — | $86M |
| Mar '22 | $23M | $12M | 85.5% | 43.3% | 7.9% | 6.8% | $7M | — | $97M |
| Dec '21 | $20M | $7M | 87.8% | 50.5% | 5.6% | 4.7% | $5M | — | $89M |
| Sep '21 | $30M | $11M | 89.0% | 45.3% | 11.5% | 10.9% | $11M | — | $83M |
How the market has priced CODX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Co-Diagnostics, Inc.'s revenue has declined 61.6% per year. These are computed facts, not advice.
As of FY2025, Co-Diagnostics, Inc. reported — of total debt against $12M of cash.
In FY2025, gross margin was 64.3%, operating margin -8058.8%, and net margin -7550.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.